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Trial registrationTo date, the scientiﬁc process for generating, interpreting, and applying knowledge has received less
informatics attention than operational processes for conducting clinical studies. The activities of these
scientiﬁc processes – the science of clinical research – are centered on the study protocol, which is the
abstract representation of the scientiﬁc design of a clinical study. The Ontology of Clinical Research
(OCRe) is an OWL 2 model of the entities and relationships of study design protocols for the purpose
of computationally supporting the design and analysis of human studies. OCRe’s modeling is independent
of any speciﬁc study design or clinical domain. It includes a study design typology and a specialized mod-
ule called ERGO Annotation for capturing the meaning of eligibility criteria. In this paper, we describe the
key informatics use cases of each phase of a study’s scientiﬁc lifecycle, present OCRe and the principles
behind its modeling, and describe applications of OCRe and associated technologies to a range of clinical
research use cases. OCRe captures the central semantics that underlies the scientiﬁc processes of clinical
research and can serve as an informatics foundation for supporting the entire range of knowledge activ-
ities that constitute the science of clinical research.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Interventional and observational human studies are crucial for
advancing our understanding of health, disease, and therapy. Clin-
ical research informatics (CRI) is ‘‘the use of informatics in the dis-
covery and management of new knowledge relating to health and
disease’’ [1]. To date, CRI has focused on facilitating conduct of clin-
ical trials and management of clinical data for secondary research
use. Yet clinical research is fundamentally a scientiﬁc pursuit, and
foundational methods for CRI should support the science of clinical
research: asking the right question, designing rigorous protocols,
conducting protocol-adherent studies, fully reporting all results,
and ﬁnally, making inferences and applying research results to care
decisions and policy.
The underpinning of this broad range of knowledge tasks is the
study protocol as the study’s conceptual scientiﬁc structure. The
planned study protocol drives all key scientiﬁc and biomedicalactivities during study execution and analysis, while the executed
study protocol represents the study activities that actually took
place. Early CRI work relegated support of protocols to the elec-
tronic sharing of text-based study protocol documents. More re-
cently, study protocols have been reiﬁed into data models (e.g.,
BRIDG [2,3]) geared towards supporting the execution of clinical
trials intended for submission to the U.S. Food and Drug Adminis-
tration (FDA) for regulatory approval of therapeutic products, or
supporting data management of clinical trial results (e.g., OBX [4]
and CDISC [5]).
To provide knowledge-based support for the scientiﬁc tasks of
clinical research, the study protocol should be modeled in a knowl-
edge representation formalism with clear, consistent and declara-
tive semantics that support drawing clinical conclusions from
study observations. The Ontology of Clinical Research (OCRe) is
such a model. OCRe is an OWL 2 ontology of human studies, de-
ﬁned as any study collecting or analyzing data about humans that
explore questions of causation or association [6,7]. OCRe models
the entities and relationships of study designs to serve as a com-
mon semantics for computational approaches to the design and
analysis of human studies.
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present highlights of the OCRe model, and review examples of how
OCRe supports the science of clinical research. Our use cases illus-
trate why clinical and research informatics need to be more deeply
integrated [8], to create a ‘‘learning health system’’ [9] that gener-
ates best evidence and also ‘‘drive[s] the process of discovery as a
natural outgrowth of patient care’’ [10]. We posit that the study
protocol, representing the essence of clinical research, is the epis-
temological foundation for a learning health system and that OCRe,
representing study protocol elements, is a core informatics founda-
tion for clinical research science.2. Motivating use cases and background
To show the value of OCRe across the breadth of clinical re-
search science, we describe its role in the ﬁve phases of a human
study’s idealized scientiﬁc lifecycle: (1) review and interpretation
of results of previous studies to reﬁne a scientiﬁc question; (2) de-
sign of a new study; (3) study execution; (4) results reporting; and
(5) interpretation and application of the results to clinical care or
policy (Fig. 1). In a learning health system, clinical practice com-
pletes the cycle as a source of new scientiﬁc questions. The ﬁve
phases of a study’s lifecycle are closely related and iterative (Fig. 1).
This remainder of this section presents use cases for each of the
ﬁve phases. Based on these use cases, Section 3 presents the foun-
dational capabilities that would transform informatics support for
clinical research and describes the OCRe model. Section 4 then ap-
plies OCRe to selected use.
2.1. Pose a scientiﬁc question, retrieve and interpret prior studies
The ﬁrst step of a clinical study’s lifecycle is highly iterative: po-
tential scientiﬁc questions are posed and revised many times as
prior studies are retrieved and interpreted over time.
2.1.1. Retrieve prior studies
Investigators often frame their research questions using the
‘‘PICO’’ mnemonic (for Patient, Intervention, Comparison, Outcome
[11], sometimes with a T added for outcome timing [12]). For
example, a broad initial question about vitamin D and cardiovascu-
lar risk (e.g., ‘‘does vitamin D supplementation reduce LDL choles-
terol levels?’’) could be phrased as Intervention = vitamin D and
Outcome = cardiovascular endpoints (e.g., hypertension, highFig. 1. Idealized scientiﬁc lifecycle of a humacholesterol, body weight). Running this PICO query at the PubMed
PICO interface [13] returned 265 studies on vitamin D’s effect on
high cholesterol (hyperlipidemia) at the writing of this paper.
These results are not directly helpful to an investigator because
the PICO structures of these studies are buried within PDFs. A bet-
ter search interface might be CTSearch with its interactive tag
cloud PICO display [14], or interactive visualizations of the scien-
tiﬁc structure of human studies like the tools that biomedical
researchers have for visual exploration and query of gene se-
quences, pathways, and protein structures.
Even so, PICO elements alone are insufﬁcient to support the full
retrieval task. Different study objectives are best addressed by dif-
ferent study design types [15]. PubMed Clinical Queries [16] allows
narrowing a search to appropriate study designs (e.g., prospective
cohort studies to explore the association of vitamin D levels with
cardiovascular outcomes, randomized controlled trials (RCTs) to
explore questions of therapy), but two major problems attend this
approach. First, this interface returns 2247 citations for a Narrow
search for Therapy studies of vitamin D. An investigator would still
need visualizations that reveal PICO and study-design features of
large numbers of studies. Second, because there is no established
study-design taxonomy, design types are poorly indexed in Pub-
Med entries and searches by design type are correspondingly inac-
curate [17]. There have only been a handful of published study-
design taxonomies [18–20], including the Cochrane Collaboration’s
taxonomy [21] and Hartling’s which showed a reliability of
j = 0.45 and is the basis for an AHRQ taxonomy [17]. In Sec-
tion 3.2.1, we describe our OCRe-based study-design typology,
which showed a moderate inter-rater agreement of Fleiss’ kappa
of 0.46 in a preliminary evaluation [22].
2.1.2. Interpret prior studies
Once investigators have retrieved a set of relevant studies
whose designs are appropriate for the scientiﬁc question, they
need to assess their evidentiary strength [23]. In statistical terms,
they need to appraise the ‘‘internal validity’’ of each study, includ-
ing the comparability of comparison groups and the existence and
nature of follow-up bias [24], Critical appraisal remains somewhat
of an art, as many study quality scales and bias instruments are
poorly correlated, imprecise, and irreproducible [25,26]while not
predictive of observed effects [27].
Many researchers lack the methodological skills embodied in
guides like those from JAMA [28], BMJ [29], the Cochrane Collabo-
ration [30], and others [31] to carry out these appraisal tasks.n study within a learning health system.
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relevant computational methods for automated critical appraisal,
no computer-based tools are widely available to provide knowl-
edge-based decision support for this critical task. A crisp, comput-
able formulation of study design and study-design strength like
OCRe would underpin this ﬁeld (see Section 4.3). In contrast, major
clinical research models such as BRIDG and CDISC SDTM [34] serve
operational and administrative needs, but do not attempt to model
study validity, confounding, and bias needed for assessing study-
design strength.
2.2. Design a new study
There are persistent concerns about the quality of the design of
human studies [35]. In 1994, Altman called the prevalence of poor
medical research a ‘‘scandal’’ [36]. In a 2005 survey, 13% of NIH
grantees acknowledged using ‘‘inadequate or inappropriate re-
search designs’’ [37]. Decision support for study design has tradi-
tionally revolved around sample size planning, pharmacokinetic
simulation, complex drug-disease modeling [38], or person/socie-
tal level simulation [39], but has not covered the full breadth of
common design shortcomings. Investigators would beneﬁt from
methodological decision support at the point of design on:
 Recommending appropriate study design types based on the
research question.
 Deﬁning the appropriate study population by querying a library
of computable designs and comparing the content and selectiv-
ity of the investigator’s initial criteria with those of related
studies.
 Identifying biases that should be taken into account at the
design phase by querying for biases most important for the rec-
ommended design.
 Identifying potential clinical confounders to be accounted for in
the design by mining prior articles and outcomes databases.
 Drawing on historical cohort identiﬁcation and past recruit-
ment patterns for sample size calculations.
Broad tools like Design-a-Trial [40] start to get at these issues
but have made little impact in part because they require ongoing
maintenance of methodological and clinical knowledge bases,
and do not incorporate knowledge from prior studies or outcomes
data. By modeling the notion of bias and confounding into OCRe,
we have begun to provide an informatics foundation for study de-
sign decision support, as discussed in Section 4.3 below.
2.3. Execute the study
Study execution steps include IRB application, study set-up,
study registration, recruitment and enrollment of participants,
protocol execution, and adverse events monitoring and reporting.
The CRI ﬁeld has developed many tools and methods for these
tasks (reviewed in [41]). A computable study protocol model could
serve to integrate these tools across the study lifecycle phases
(Fig. 1). In particular, a computable representation of eligibility cri-
teria is useful for cohort identiﬁcation and eligibility determination
for study execution and for determining the applicability of studies
to a target patient or population.
Cohort identiﬁcation refers to computer-based matching of a
study’s eligibility criteria against clinical data (e.g., an EHR) to
identify a cohort of potentially eligible patients. Eligibility determi-
nation is the converse problem: matching one patient’s EHR data
against a database of studies and their eligibility criteria to identify
studies that the patient may be eligible for. In both cases, a prose
criterion needs to be transformed into a computable representa-
tion, and then matched against EHR data. Complicating this taskis the complexity of eligibility criteria. In an analysis of 1000 ran-
domly drawn eligibility criteria from ClinicalTrials.gov, Ross et al.
found signiﬁcant semantic complexity, with 20% of criteria having
negation, 30% having two or more complex semantic patterns, and
40% having temporal features [42]. Given these complexities, the
state of the art in formalizing eligibility criteria is still rudimentary
[43], as is eligibility determination performance. Cuggia found that
among 28 papers reporting on clinical trial recruitment support
systems, most were small scale tests that were not formally evalu-
ated, none matched criteria against unstructured patient notes,
and very few systems used interoperability standards [44]. OCRe
includes a model of eligibility criteria capable of capturing much
of their observed semantic complexity as discussed in Section 3.3
below.
2.4. Register and report the study
For clinical research to advance care and science, study results
and the study designs that gave rise to those results must be fully re-
ported. Indeed, transparent, unbiased study registration and
reporting of interventional studies is a fundamental ethical duty
as codiﬁed in the Declaration of Helsinki [45], and is arguably an
ethical duty for observational studies as well [46]. OCRe provides
a common ontology for describing study designs that can comple-
ment both registration and study reporting. Study reporting is
going ‘‘beyond PDF’’ as medical journals move towards publishing
full datasets (e.g., BMJ [47], Trials [48], Annals of Internal Medicine
[49]), and as regulatory agencies like the European Medicines
Agency begin to require disclosure of individual-patient level data
[50]. To ensure retrieval of all relevant studies (see Section 2.5.1),
federated data querying will be needed across these data sources
as well as trial registers and other trial databases (e.g., AHRQ’s Sys-
tematic Review Data Repository, Cochrane’s Central Register of
Studies). OCRe can serve as a well-formed semantics for federated
data querying of study designs, as we discuss below for the Human
Studies Database project (Section 4.1.3).
2.5. Synthesize bodies of evidence and apply to care and policy
While study reporting is the last interaction of an investigator
with a study, the study itself lives onto be retrieved, interpreted,
synthesized with other studies, and applied to clinical care or pol-
icy. In the Application phase of a study’s lifecycle, we become
interested in the entire body of evidence for a clinical or policy
question, and less interested in single studies in isolation [51].
The evidence application subtasks include retrieving evidence,
synthesizing it, and applying it in a learning health system.
2.5.1. Identifying and retrieving whole bodies of evidence
To ensure that clinical or policy decisions are made on best
available evidence, all relevant studies and their full results need
to be identiﬁed and retrieved. As study results become available
through textual and database sources such as trial registers, jour-
nal publications, and regulatory databases, a federated search ap-
proach becomes necessary. Because study design greatly affects
the validity of clinical research results, retrieval of bodies of evi-
dence must also include retrieval by study design features. In our
Human Studies Database (HSDB) project, we used OCRe to demon-
strate federated query access to study protocol information from
multiple academic medical institutions [7] (Section 4.1.3). In Sec-
tion 4.2, we also describe how OCRe can be used to conceptualize
study retrieval as a phenotype-matching problem. The PICO-based
phenotype of a study comprises its enrolled population, the inter-
vention(s) tested, the outcomes assessed, and key clinical and non-
clinical covariates (e.g., care setting). This study phenotype can be
matched to a search query, to another study to determine study
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determine study applicability.
2.5.2. Systematic review
A high quality systematic review of high quality randomized tri-
als is now the gold standard clinical evidence for questions of ther-
apy [52]. Systematic reviews of other study designs are also critical
for evidence-based medicine. Systematic reviews are, however,
very time and labor intensive and current practices are not sufﬁ-
cient to keep up with the ﬂood of new studies [53]. The holy grail
of automated systematic reviews [54] remains elusive for both
technical and methodological reasons. Current systems are mainly
workﬂow support tools like the Cochrane Collaboration’s RevMan
[55] and AHRQ’s SRDR system [56] that do not provide knowl-
edge-based support for comparing, critiquing, and meta-analyzing
studies. Meta-Analyst, now available as OpenMetaAnalyst [57],
was one of the earliest decision support systems for meta-analysis
with a Bayesian model of studies at its core. A fuller model of study
designs and their attendant biases could offer a foundation for
knowledge-based systematic review systems and for their interop-
eration with other phases of the study lifecycle. This is a wide-open
area for substantial advances in clinical research informatics.
2.5.3. Evidence application and the learning health system
Rather than a one-way pipeline of research evidence to practice,
translational medicine embraces the concept of a learning health
system in which evidence is both applied and generated at the
point of care. In this vision, the study lifecycle intertwines with
the care system, and the informatics requirements discussed above
become pertinent to frontline health information systems as well.
Although clinical research and clinical informatics are still more
separate than they should be [8], research innovations such as
‘‘point of care research’’ [58] embedded n-of-1 studies [59,60]
and digital epidemiology [61] are knocking down silos between
clinical research and health care informatics. By modeling study-
design features and eventually study results, OCRe places human
studies in a formally characterized relationship to patient data,
and provides an epistemologically sound informatics foundation
for clinical research and the learning health system.
3. The OCRe ontological infrastructure
The above use cases describe clinical research as a scientiﬁc
enterprise with a wide range of informatics requirements. We
identify the following requirements as representing the founda-
tional capabilities that would transform informatics support of
clinical research.
(1) Ability to describe a study’s PICOT structure and the design
of the study that facilitates identiﬁcation and classiﬁcation
of studies in term of their scientiﬁc and design features
(use case Section 2.1.1).
(2) Ability to ensure the completeness and internal coherence of
study instances (use cases 2.2 and 2.4).
(3) Ability to ingest and instantiate study metadata from multi-
ple manual and electronic sources (use case 2.4 and also a
pre-requisite of requirement 4).
(4) Ability to query for ontology-conformant study instances
within or between institutions, using concepts from the
ontology as well as from controlled vocabularies (use cases
2.1.1 and 2.5.1).
(5) Ability to assist or enable selected tasks in the execution of a
study (use case 2.3).
(6) Ability for investigators to visualize and assess the strengths
and weaknesses of study designs either singly or in the
aggregate (use cases 2.1.2 and 2.5.1).(7) Ability to incorporate assessments of evidentiary strength
into results interpretation, synthesis, and application (use
cases 2.1.2 and 2.5).
At the core of these capabilities is a unifying representation of
the study protocol. We wish to classify and query studies by their
PICOT characteristics and by their design characteristics. We wish
to constrain relationships among components of study protocols
by placing various types of restrictions. We decided that descrip-
tion logic, in the modern form of Web Ontology Language (OWL),
provides the most expressive and tractable knowledge representa-
tion formalism for capturing the formal semantics of study
protocols.
The ﬁrst three requirements above call directly for an ontolog-
ical infrastructure upon which speciﬁc methods can be developed
to address the use cases described in Section 2. At the center of
our framework is an Ontology of Clinical Research (OCRe) and, as
part of it, a study design typology that serves as the reference
semantics for reasoning and data sharing. We developed OCRe to
satisfy the ﬁrst two requirements directly, and also developed a
suite of OCRe-based approaches to address the other require-
ments: a data representation format and data acquisition methods
for requirement #3; data federation technologies for requirement
#4; an eligibility criteria annotation method for requirement #4
and #5; visualization methods for requirement #6; and represen-
tational and analytic methods for requirement #7.
In this section, we ﬁrst review the ground methods and princi-
ples behind the development of OCRe. Then we describe OCRe’s
major components, including a study-design typology and ERGO
Annotation for capturing eligibility criteria. Finally, we describe
how XML schemas can be generated from OCRe and used for data
acquisition and use-case-speciﬁc querying.
3.1. Methods and principles of modeling
Rector [62] makes a distinction between representations of the
world (models of meaning) versus data structures (information
models). Models of meaning make formal statements about enti-
ties and relationship in the world. Information models (e.g., Health
Level 7 Reference Information Model [63]) specify which data
structures are valid for the purpose of exchanging and reusing
them in different information systems. Usually models of mean-
ings are formulated as ontologies using logic-based representa-
tions such as OWL. Information models may be represented in
OWL or object-oriented languages such as Uniﬁed Modeling Lan-
guage (UML). While most other CRI models, e.g., CDISC’s Study De-
sign Model [34], are information models, OCRe encapsulates both
models of meaning and information models. On one hand, we con-
ceptualize a study as a real-world entity and we use the OWL for-
malism to make assertions about the structural components and
features of human studies as well as assertions about particular
studies. The core structures of a study protocol, including the de-
sign typology, design features, subgroups in the study, and inter-
ventions and exposures, are readily captured in the OWL
formalism. On the other hand, some aspects of study design – eli-
gibility criteria in particular – are difﬁcult to formulate ontologi-
cally and are better modeled using an informationmodel approach.
To illustrate, the eligibility criteria of a study deﬁne the target
population of the study in terms of descriptions that may involve
prior assessments, treatments, and test results and their temporal
relationships. An ontological modeling of such descriptions is ex-
tremely complex and non-scalable. Instead of attempting to for-
malize such complex descriptions, we deﬁned an information
model called ERGO Annotation that allows us to annotate the cri-
teria more simply but still capture the essential meaning of the cri-
teria. These annotations, while not direct assertions about the
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cation of natural language processing (NLP) methods to automate
the recognition of coded concepts and relations in free-text eligi-
bility criteria and that can be transformed into computable formats
to satisfy use cases from the lifecycle of studies that require the
characterization of subject populations. Recently, we re-formu-
lated ERGO Annotation, previously represented in Protégé’s frame
language, as a component of the OWL-based OCRe, and extended
the syntax to capture temporal and non-temporal constraints on
entities and events referenced in eligibility criteria. Representing
such informational model entities in OWL serves two purposes:
(1) it enables, within a single representation, the transformations
of the annotations into OWL expressions so that we can reason
about a study’s target population; and (2) it completes the repre-
sentation of a study in a single formalism so that applications
can reason about a study’s target population together with other
components of the study protocol. Section 3.3 presents more de-
tails about this hybrid modeling approach.
A potential point of confusion is that much of what we are mod-
eling, such as the description of a study in a clinical trial protocol,
are informational entities themselves. For example, a study proto-
col contains speciﬁcations of what phenomena the study variables
represent or operationalize and at what frequency and how they
should be measured. Similarly, instead of actual interventions that
are carried out, the protocol speciﬁes how interventions should be
performed on study subjects. We model the structural components
of these informational entities. For example, a protocol contains
speciﬁcations of subgroups whose members may be subject to dif-
ferent interventions or exposures. We also model these informa-
tional entities in terms of their characteristic descriptors. For
example, a protocol may specify that it has a parallel group study
design, which is deﬁned as an interventional design that has two
design descriptors (written in Courier font): having multiple
regimens and making main comparison across experimental
units. We represent the relationships between descriptor-based
and structural-based descriptions as axioms that must hold. A sim-
ple example is that a study with a design descriptor of multiple
regimen must contain more than one study arm (sub)population.
These axioms can be used as integrity constraints to check the con-
sistency and completeness of a study speciﬁcation, as described in
Section 4.1.2.
Another point of contact between OCRe and informational enti-
ties is in OCRe’s references to controlled terminology. OCRe models
the design of human studies, as expressed in study protocols, inde-
pendent of any speciﬁc clinical domain. Study protocols, as infor-
mational entities, make references to real world phenomena
through natural-language text or through structured codes. In
OCRe, the semantics of clinical content are expressed through ref-
erences to external ontologies and terminologies such as SNOMED.
OCRe entities (e.g., outcome phenomenon) are related to external
clinical concepts (e.g., acute myocardial infarction) through termi-
nologies and their associated codes (e.g., SNOMED code for acute
myocardial infarction). Thus, if we strip labels that are necessary
to aid human understanding from clinical concepts referenced in
OCRe, we have a formal and machine-processable representation
of a study description.
Besides being domain independent OCRe is also independent of
the requirements of speciﬁc applications in the way it models the
entities and relationships of human studies. We made the decision
that the semantics of application-speciﬁc ontological extensions
must be expressible in terms of the underlying OCRe concepts.
For example, our HSDB project to federate descriptions of human
studies among CTSA institutions [7] deﬁned an extended OCRe
model called HSDB_OCRe that has additional categories of roles
speciﬁc to our CTSA use case that organizations can play.
HSDB_OCRe also implements ‘‘shortcuts’’ in navigating OCReentities and relationships to enable the efﬁcient acquisition and
federated querying of large volumes of study information. These
shortcuts add no additional semantic content, but create alterna-
tive categories that are convenient for application purposes. For
example, OCRe reiﬁes Funding as a class of administrative relation-
ship associated with studies, where the reiﬁed relationship is iden-
tiﬁed by some funding number and has some person or
organization as actors. This reiﬁcation is necessary because a study,
its funder, and the funding number represent an n-ary relationship
that cannot be captured directly using OWL’s binary properties. It
is not necessary, however, for OCRe to have a Funder class because
this category can be derived completely as a deﬁned class in OWL.
Nevertheless, in the HSDB project, we found it convenient to have a
Funder class and a ‘has funder’ object property fully deﬁned in
terms of underlying OCRe concepts. In this way, OCRe can be ex-
tended to satisfy arbitrarily different use cases without having to
model those use case domains directly.
A different challenge arises in satisfying the requirement of
instantiating study design information in OCRe-compliant form.
A formal ontology such as OWL consists of a collection axioms
and additional assertions that can be inferred using the Open
World Assumption (OWA): an assertion is possibly true unless it
can be explicitly shown to be false. There is no requirement that
a speciﬁc collection of facts has to be asserted explicitly. As a con-
sequence, completeness of data entry cannot be checked, unless
we add closure axioms to say that only explicitly asserted data ele-
ments exist. Furthermore, an OWL class does not ‘‘own’’ a set of
properties in the sense of having a set of attribute or participating
in a set of relationships. It is not appropriate, therefore, to instan-
tiate descriptions of speciﬁc studies into OCRe OWL. Rather, a data
model (schema) is needed, consisting of templates of ﬁelds and va-
lue sets for acquiring entities and relationships in a domain. For
these reasons, the OCRe infrastructure includes a method for
extracting data models suitable for the acquisition and mainte-
nance of large amounts of instance data for speciﬁc use cases, as
described in Section 3.4.
3.2. The OCRe OWL model
OCRe is organized as a set of modular components with the
main modules related by import relationships as shown in Fig. 2.
The ontology is modularized into a main OCRe.owl ontology and
sub-ontologies for study design (study_design.owl), the plan com-
ponents of a study protocol (study_protocol.owl), and statistical
concepts related to the speciﬁcation of study analysis (statis-
tics.owl). Earlier descriptions of OCRe, the genesis of the study-de-
sign typology and the application to the HSDB project are
presented in [6,7,22].
As mentioned earlier, the HSDB Project extended OCRe with
HSDB-speciﬁc concepts that are fully deﬁned in terms of OCRe con-
cepts. The main HSDB_OCRe ontology imports the extended OCRe
and also uses a set of annotation features (deﬁned in export_anno-
tations_def.owl) to specify ontology elements that should be ex-
ported as part of a HSDB_XSD (Section 3.4).
3.2.1. Study design typology
Study data should be interpreted within the context of how
those data were collected (e.g., interventional versus observational
study) and the purpose for which they were intended (e.g., public
health versus regulatory ﬁling). Since each study type is subject to
a distinct set of biases and interpretive pitfalls, a study’s design
type strongly informs the interpretation and reuse of its data.
Through iterative consultation with statisticians and epidemiolo-
gists, we deﬁned a typology of study designs based on discriminat-
ing factors that deﬁne mutually exclusive and exhaustive study
types [22]. For example, whether the investigator assigns one or
Fig. 2. OWL import graph for OCRe.
Fig. 4. The hierarchy of study-design characteristics.
I. Sim et al. / Journal of Biomedical Informatics 52 (2014) 78–91 83more interventions discriminates between interventional and
observational studies (Fig. 3).
The typology classiﬁes studies hierarchically into four interven-
tional and four observational high-level design types. Additional
descriptors elaborate on secondary design features that introduce
or mitigate additional interpretive features: eight additional
descriptors for interventional studies (e.g., comparative intent
(superiority, non-inferiority, equivalence); sequence generation
(random, non-random)) and six additional descriptors for observa-
tional studies (e.g., sampling method (probability, non-probabil-
ity); whether samples matched on covariates). Each descriptor
applies to one or more of the main study types: for example, se-
quence generation applies to all of the interventional study types
except single group; sampling method applies to all of the observa-
tional study types. This typology is available at <http://hsdbwi-
ki.org/index.php/Study_design_typology>.
We incorporated this study design typology into OCRe in the
form of an OWL hierarchy in the study-design module (Fig. 2). For-
mally, the study-design descriptors are represented as a hierarchy
of ‘‘study-design characteristics’’ (Fig. 4). A particular study design
is then deﬁned in terms of its parent design and the descriptors
that differentiate it from its siblings. Fig. 5 shows the deﬁnition
of a parallel-group design in terms of design characteristics, to
illustrate the distinctions that are made in OCRe.Fig. 5. The OWL deﬁnition of a parallel group study design.3.2.2. Study arms and interventions
OCRemodels both interventional and observational studies. The
Code of Federal Regulation 45 CFR 46 deﬁnes a study intervention
as ‘‘manipulations of the subject or the subject’s environment thatFig. 3. The study design typology.
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or combinations of interventions (i.e., regimens) are attached to
arms and study participants are assigned to these arms. Depending
on the objective of the analysis, subjects can then be grouped
(independent variable) by the intervention they were originally as-
signed to (intention-to-treat analysis) or the intervention they re-
ceived (as-treated analysis). In observational studies, the
independent variables for study analyses are called exposures, be-
cause they are not manipulated (i.e., assigned) by the study
investigator.
3.2.3. Study outcomes and analyses
As we described in a previous paper [6], the study protocol
speciﬁes study activities (e.g., intervention assignment, data collec-
tion) that relate to the generation of observations, which are then
analyzed to support or refute study hypotheses. To model these
relationships, OCRe ﬁrst deﬁnes a study phenomenon as ‘‘a fact
or event of interest susceptible to description and explanation.’’
Study phenomena are represented by one or more speciﬁc study
variables that may be derived from other variables. For example,
the study phenomenon of cardiovascular morbidity may be repre-
sented as a composite variable derived from cardiovascular death,
myocardial infarction (MI), and stroke variables. Each variable can
be further described by its type (e.g., dichotomous), coding (e.g.,
death or not), time points of assessment (e.g., 6 months after index
MI), and assessment method (e.g., death certiﬁcate). All variables
are associated with participant-level and group-level observations.
A study protocol may specify several analyses, each having depen-
dent and independent variables that represent various study phe-
nomena. A variable may play the role of dependent and
independent variable in different analyses. If the study protocol
designates a primary analysis, the dependent variable of that anal-
ysis represents what is conventionally known as the primary out-
come of the study. To our knowledge, OCRe is the ﬁrst model to
disambiguate study phenomena of interest from the variables that
code observations of those phenomena, and from the use of those
variables in study analyses. This clarity of modeling should provide
a strong ontological foundation for scientiﬁc query and analysis for
clinical research.
3.3. ERGO annotation
Based on the previously described analysis of study eligibility
criteria [42], and because of the issues discussed in Section 3.1,
we reformulated the problem of representing eligibility criteria
from that of formally encoding criteria in some machine-process-
able expression language to that of classifying and decomposing
criteria by identifying noun phrases that capture the basic meaning
of the criteria and formalizing the noun phrases as coded termino-
logical expressions [65]. We emphasize that there is closure on the
representation of all concepts as controlled terminologies or CUIs
from UMLS. An ERGO Annotation statement can be of three types:
(1) simple statement that makes a single assertion using a noun
phrase that may have recursive modiﬁers, (2) comparison criterion
that is a triplet denoting a measurement value (signiﬁed by a noun
phrase like ‘‘white blood cell count’’) a comparison operator (e.g.,
‘‘greater than’’) and a quantitative threshold (e.g., 5000/mm3),
and 3) complex statement, which is composed of multiple state-
ments joined by AND, OR, NOT, IMPLIES, or semantic connectors,
such as ‘‘caused by.’’ For example, ‘‘Tuberculosis of intrathoracic
lymph nodes, conﬁrmed histologically’’ is a simple eligibility crite-
rion with a long noun phrase that is decomposed into a root simple
noun phrase (tuberculosis) modiﬁed by location (intrathoracic)
and by the modiﬁer conﬁrmed_by (histology).
In our current work, we augmented the representation of noun
phrases to take into account meaning-altering contexts such as‘‘family history of’’. We formulated a constraint framework with
different types of constraints. One type is restrictions on values
of measurements. Other types are constraints on events (repre-
sented by noun phrases, e.g., diagnosis of breast cancer) by qualiﬁ-
cation of entities, or semantic or temporal relationships among
entities and events. The temporal restrictions may be a duration
constraint (e.g., event duration <2 weeks), a time-point constraint
that compares the time of the constrained event to that of another
event (e.g., 3 weeks after end of chemotherapy), or a time-interval
constraint where the time interval associated with the constrained
event is compared with another time interval using Allen’s tempo-
ral-interval comparison operators [66]. Take for example, ‘‘Pres-
ence of bone marrow toxicity as deﬁned by WBC <4000 3 weeks
after the end of chemotherapy.’’ Here, ‘‘Bone marrow toxicity’’ is
the root noun phrase representing the occurrence of some event,
and ‘‘deﬁned by’’ is a semantic relation that links it to a complex
ERGO Annotation statement consisting of WBC (a noun phrase)
constrained by a numeric value constraint (<4000). ‘‘Bone marrow
toxicity’’ is further restricted by the time-point constraint stating
that the time of bone marrow toxicity is after a time point deﬁned
by ‘‘3 weeks after the end of chemotherapy.’’3.4. OCRe XSD data models
OCRe’s OWL model is an abstract generic model of the domain
of human studies. We previously reported on the rationale for
choosing XML Schema as the template formalism [6,7] for acquir-
ing instances of study descriptions. Brieﬂy, we deemed UML too
cumbersome for mapping from OWL for our purpose. Without tool
support, generating an UML model from an OWL ontology means
creating the model in its serialized XMI format. XML Schema, on
the other hand, is easy to use, supported by many tools, and fol-
lows the closed world assumption (i.e., XML schema types are tem-
plates), and has relatively simple serialized XML format. RDF, by
contrast, is open world and does not provide a template for tar-
geted export from relational databases, the most common source
format for studies. But by keeping our XSD conformant with the
logical structure of OCRe, OCRe XML instances can be translated
into RDF/OWL format for advanced reasoning.
To ensure that instance data acquired using the schema are con-
sistent with the OCRe ontology, we developed a data-model extrac-
tor to automatically derive an XSD ﬁle from annotations on OCRe
entities. To generate an XSD, annotations are made in OCRe to
specify: the root class for the XSD, the properties that should be
represented as element tags in an XSD complex type, the subclass-
es to export as additional complex types, the parent class to use as
the extension base in case there are multiple parents, and how va-
lue sets for property values should be created from ontology enti-
ties (e.g., treating individuals or subclasses of class as
enumerations of values). The data-model extractor then acts on
these annotations and uses property range axioms and property
restrictions on classes to specify the types and constraints on spe-
ciﬁc XSD elements. For each type and data element in the XSD, its
source in the ontology is clearly indexed using Semantic Annota-
tions for SWDL (SASWDL), as shown in Fig. 6.
The end product of this process is an XSD schema deﬁnition for
a hierarchical XML data model. Our automated XSD generation ap-
proach allows changes in OCRe OWL to automatically propagate to
the XSD and from there to the schemas of local databases, where
programmatic approaches can update XML instance data to con-
form to the revised XSD as necessary. In summary, our OCRe
data-model extraction process allows different XSD data models
to be generated from different sets of annotations in extensions
of OCRe, thus allowing OCRe to support acquisition of instance data
for different use cases.
Fig. 6. Example of an XSD element (StudyDesign) indexed to OCRe entity OCRE100056 via a URI. StudyDesign is associated with a 15-element value set partially shown in this
ﬁgure.
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This section illustrates the types of methods and solutions made
possible with OCRe. First, we brieﬂy review prior work on how
study instances can be captured in XSD and exposed for federated
querying with OCRe as the reference semantics. Next, we describe
how a study’s PICO characteristics constitute a ‘study phenotype’,
and propose methods that use study phenotypes to: (1) match
studies to a search query; (2) match studies with each other to
identify ‘‘similar’’ studies; and (3) match studies to patient data
to determine study eligibility. Finally, we introduce the idea of
OCRe-indexed bias models and methods for identifying clinical
confounders as the basis for computational reasoning about the
evidentiary strength of studies, Table 1 shows how these methods
address the study lifecycle use cases described in Section 2.4.1. OCRe-based protocol instantiation and query
Instantiation of study descriptions in OCRe poses both technical
and socio-technical challenges. Extraction of study descriptions
from clinical trial management systems and electronic IRB systems
is limited by incomplete and mostly-text-based information as
well as vendor access issues [6]. Protocol documents and journal
articles are likewise in free text and highly variable in content.
Here we summarize work we have described elsewhere [7] on
semi-automated and NLP approaches to data acquisition into OCRe
semantics, and on federated data querying using OCRe semantics.4.1.1. Instance acquisition
Our HSDB use case was data federation of descriptions of study
designs among CTSA institutions. Using the HSDB_XSD data model
described in 3.4, we can acquire instances in several ways. With
Rockefeller University (RU), we piloted ETL of study design infor-
mation from their Oracle-based iMedRIS e-IRB system [7]. Brieﬂy,
RU used HSDB_XSD to deﬁne SQL queries that mapped constructs
of the schema to the iMedRIS relational tables. They then used Ora-
cle’s DBMS_XMLGEN PL/SQL supplied package to issue the SQL-
based ETL queries and convert the results ‘‘on the ﬂy’’ into XML in-
stances. An XSL Transform (XSLT) stylesheet was used to transform
canonical XML into the XSD-compliant format, and manual post-
processing data cleanup and XML validation was performed with
the Oxygen editor. With ClinicalTrials.gov, we performed bulkTable 1
OCRe-based Methods and Study Life Cycle Phases. The U ’s denote applications of an OCR
Life cycle phase Instantiation and Query Study Ph
Constraint Checking Federated Query PICO
Study retrieval U U U
Study interpretation U U U
Study design U U U
Study execution U
Study reporting U
Results application U UETL of their data. First, we mapped elements from ClinicalTri-
als.gov’s XSD to corresponding elements in HSDB_XSD using XSLT
[7]. ClinicalTrials.gov entries were then downloaded from their API
as separate ﬁles and each ﬁle was transformed into HSDB_XML
ﬁles using the Saxon XML processor and XSLT.
NLP approaches are also indicated given that the bulk of study
design information is in protocols and journal publications. Exam-
ples abound of methods to extract key trial elements such as pop-
ulation description, interventions, and outcomes [67–71] or PICO
design features [72]. We ourselves developed the ExaCT semi-auto-
mated system for acquiring study-design data from full-text pa-
pers [73], as well as NLP techniques to analyze and instantiate
eligibility criteria into ERGO Annotation [65]. While none of these
systems yet use OCRe-XSD, they can now use OCRe-XSD templates
as a common target data schema.4.1.2. Constraint checking
OCRe’s declared semantics allows for constraint checking at the
logical level (using extensions of OWL to enable constraint check-
ing [74,75]), at the data model level (using XSD constraints), and
programmatically, based on distinctions in OCRe. These con-
straint-checking methods can assist with data curation. For exam-
ple, in reviewing study records from ClinicalTrials.gov, we noticed
several types of recurring errors [7,76]. Guided by our OCRe model,
we elucidated a number of constraints that could be used to curate
these errors, including (using ClinicalTrials.gov names):
(1) All data elements under Study Design should be completed,
and N/A used where a speciﬁc item is not applicable (e.g.,
Phase should be ‘‘N/A’’ for behavioral studies).
(2) If Allocation = Randomized, then
(i) Study type must be Interventional
(ii) Intervention Model must be Parallel or Crossover
Assignment
(iii) Number of arms must be > 1.
(3) If Intervention Model = Single Group Assignment, then
(i) Number of arms must be = 1
(ii) Allocation must not be Randomized.
(4) If Intervention Model not = Single Group Assignment, then
Number of arms must be > 1.
(5) If Study type = Interventional and Title includes ‘‘placebo’’,
then there should be a Placebo Arm deﬁned and a placebo
intervention.e-based method to use cases in that lifecycle phase.
enotype Matching/Comparison Evidentiary Reasoning
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compliant instances via XSD and programmatic constraints. Apply-
ing these constraints to ClinicalTrials.gov would improve the scien-
tiﬁc accuracy of crucial information on study design and
intervention model, and would also improve derivative projects
like Aggregate Analysis of ClinicalTrials.gov (AACT) [77] and
LinkedCT.
Another example of constraint checking is for reproducible re-
search, in which third-party researchers use a study’s protocol,
dataset, and statistical code to verify and reproduce published re-
sults [78]. Having study design information in OCRe would enable
automated constraint checking and ontology-driven visualization
and interpretation of the study in the context of other related stud-
ies (e.g., CTeXplorer [79]). As medical publishing transitions ‘‘be-
yond the PDF,’’ computable models of study design like OCRe
may prove increasingly valuable.
4.1.3. Federated query using OCRe semantics
In our HSDB project, we used the Query Integrator (QI) from the
Brinkley lab [80] to query HSDB_XSD-compliant XML databases
hosted at three CTSA institutions. QI can issue Xquerys as well as
SPARQL queries to ontologies in BioPortal. This allowed us to issue
live federated queries that exploited both OCRe’s logical structure
and SNOMED’s taxonomic hierarchies using a single query formal-
ism. We were thus able to automatically ingest study data from
institutional e-IRB-based protocol descriptions, ingest the entire
ClinicalTrials.gov repository, perform inter-institutional ontology-
based queries at high granularity, and identify inconsistencies in
instance data using OCRe’s axioms [7]. This proof of demonstration
showed the value of OCRe and the feasibility of our general-pur-
pose federated query infrastructure.
4.2. Study phenotype matching
Several core clinical research use cases involve the matching of
a study’s design features against a query, other studies, or patient
data. To facilitate these matching tasks, we deﬁne a study’s ‘‘phe-
notype’’ as its PICO protocol elements. For example, consider a ran-
domized trial that tests high dose versus low dose vitamin D
supplementation for Primary Outcome Phenomenon Hyperlipidemia
and Primary Outcome Variable LDL:HDL ratiowith ‘‘HgbA1c > 6.5%’’
as one of the eligibility criteria. This study design can be repre-
sented in PICO as: Population = diabetic patients, Interven-
tion = high dose vitamin D supplementation, Comparison
Intervention = low dose vitamin D supplementation, Primary
Outcome = hyperlipidemia, as measured via the variable LDL:HDL
ratio, with Timing = 6 months.
4.2.1. Matching a study’s phenotype against a query
The study retrieval task can be construed as the matching of a
PICO query against a study’s PICO phenotype, with the semantic
distance between the two PICO vectors being a measure of rele-
vance. If we consider each dimension of PICO as an axis in a vector
space, a study’s PICO features deﬁne a subspace that we will call
the study phenotype space Sstudy_phenotype(studyA). Retrieval rele-
vance is then the semantic distance between Ssp(studyA) and Ssp(-
query). We can exploit the hierarchies in standard clinical
vocabularies to generate a distance metric D(studyA, query). The
lesser the distance, the more relevant Study A is to the query.
The relevance determination task divides into three match do-
mains: (1) study population, (2) predictors (interventions and
comparisons), and (3) outcomes and their assessment timing.
These methods will generate P-, IC-, and O- similarity scores Dpop,
Dpredictor, Doutcome for each comparison of a study to the query.
The overall similarity of a study to the query, Dstudy_phenotype(study,query), will be computed as a function of the three underlying sim-
ilarity scores. The rest of this section lays out our plan for using
OCRe for this matching. We will assume that a PICO query will con-
sist of three sets of query terms, one set for each P, IC and O
domain.
Matching study population A study’s population is most
clearly deﬁned in the eligibility criteria. (Baseline variables de-
scribe only selected features of the enrolled population). OCRe cap-
tures eligibility criteria as simple and compound statements in
ERGO Annotation (Section 3.3). After pre-processing and annota-
tion, each study’s eligibility criteria will be a Boolean combination
of noun phrases with constraints. For sake of simplicity, we will
consider cases where the constrained noun phrases are coded as
SNOMED terms or their extensions.
To match a study A’s eligibility criteria against the P of a PICO
query, we ﬁrst identify the study’s population space Spop(studyA).
This space is deﬁned as all eligibility criteria that are characterized
by the SNOMED terms that are of a ‘‘clinical’’ semantic type (e.g.,
disease, symptom, demographics, labs). The population match dis-
tance Dpop(studyA, query) is the minimal semantic distance be-
tween Spop(studyA) and Spop(query). If Spop(studyA) coincides with
Spop(query), then Dpop(studyA, query) = 0. Otherwise, Dpop(studyA,
query) is deﬁned algorithmically, as follows:
1. Step 1 – First, for each term in studyA, we ﬁnd the eligibility
term Tquery,n in the query that is semantically closest to it. Sup-
pose studyA’s ﬁrst eligibility criterion is annotated by the term
‘‘heart failure.’’ In the straightforward case, if the query includes
a SNOMED term that is a synonym of heart failure, then Dcrite-
rion1(studyA, query) = 0. Other cases are more complicated. If
the query has a population term Tquery,2 ‘‘cardiomyopathy,’’ that
term is a neighbor to studyA’s criterion ‘‘heart failure.’’ To calcu-
late Dcriterion1(studyA, query), we can use a semantic distance
function from NCBO Annotator [81,82] or Jiang et al. [83]. We
take DcriterionA(studyA, query) to be the minimum of criterion1’s
distances to any term Tquery,n in query. Thus, if all terms Tquery,n
of query are far from those of studyA, then Dcriterion1(studyA,
query) approaches 1 (i.e., no match).
2. Step 2 – If a population eligibility criterion is the disjunction or
negation of population terms A, B, C, we deﬁne
D(A or B, C) = min {D(A, C), D(B, C)}
D(A, B) = 1 - d(A, B) based on the intuition that if B is far from
A, then B is close to complement of A.
3. Step 3 – Calculate overall Dpop(studyA, query), incorporating the
distance between all criteria. At this step, we have a vector of N
dimensions, where N is the number of population eligibility
terms TA,n for studyA, and the values are the distances between
each TA,n and its semantically closest corresponding term T (if
any) in the query. We now need to collapse this vector to a sin-
gle overall population distance Dpop(studyA, query). Ideally, we
should not just sum the Euclidean distances of the vector
because the population phenotypes are likely to be correlated.
For example, studies enrolling ‘‘heart failure’’ patients are more
likely to include patients with ‘‘hypertension’’, such that two
studies matching on both these criteria match less than a study
matching on two clinically un-correlated criteria. However, this
correlation problem may not be large enough to materially
affect similarity determination for most researchers, so using
the Euclidean distance measure is a reasonable ﬁrst
approximation.
Matching interventions/comparisons In OCRe, a study’s pre-
dictor variables are described in the class outcome_analysis_spec-
iﬁcation. We can call a study’s space of predictors Spredictor(study).
For queries, Spredictor(query) is deﬁned by terms that are of seman-
tic types that are appropriate for interventions, as deﬁned for
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quence similarity scoring method developed by Lee [85,86] to de-
ﬁne a distance metric Dpredictor(studyA, query) between a study and
a query. In Lee’s method, a pattern of care refers to a set of tempo-
rally ordered, non-overlapping treatment courses. A treatment
course is a single treatment or a set of treatments (called treatment
regimen) that occurs over an interval period of time. A temporal se-
quence similarity score (T3S) between two treatment courses is
deﬁned by:
1. Constructing a similarity matrix, simE among the set of treat-
ments E = {e1, e2, ...,eN} based on distances derived from an
ontology of such treatments.
2. Deﬁning an Aligned Temporal Sequence Similarity Score (T3SA)
for two patterns of care that have the same number of treat-
ment courses, with T3SA taking into account differing durations
and compositions of matched treatment courses.
3. Deﬁning T3S for two non-aligned patterns of care as the T3SA of
the overlap regions multiplied by a weight based on the ratio of
the two patterns of care’s lengths.
There is nothing in Lee’s metric that limits its application to
interventions. It can also apply to non-treatment predictors, such
as exposures, to calculate Dpredictor(studyA, query). Additional
methods are needed for matching on deeper predictor features
for interventions and exposures (e.g., dose of a drug, indeterminate
duration of a treatment or exposure event, e.g., ‘‘treat until the
occurrence of X’’).
Matching outcomes and their assessment times Similarly,
OCRe instances will deﬁne Soutcome(study) and the query will deﬁne
Soutcome(query). To deﬁne the distance between these spaces, we
ﬁrst determine the ‘‘clinical’’ distance between the outcome vari-
ables (e.g., between ‘‘dull pain’’ and ‘‘burning pain’’), then deter-
mine the ‘‘temporal’’ distance between the assessment times of
‘‘similar’’ variables (e.g., ‘‘3 months’’ and ‘‘6 months’’). For each out-
come variable in studyA, we pair it with an outcome term in the
PICO query that is closest to it as deﬁned by NCBO Annotator’s
semantic distance function. We ﬁnd the closest temporal distance
between any pair of assessment timepoints for each outcome var-
iable/term pair, and calculate the absolute difference in time dura-
tion since time zero, which is supposed to be stated in protocols
[87–89]. We can explore heuristics for when outcomes are sufﬁ-
ciently similar semantically that calculating a temporal distance
makes sense, and investigate alternative methods for calculating
and capturing the temporal distance between two assessment
timepoints (e.g., % of difference). Finally, we combine such time
differences across multiple variable and timing pairs to calculate
Doutcome(studyA, query). Methods for more complex matching
(e.g., stroke documented by MRI vs. stroke coded as a discharge
diagnosis) are beyond the scope of this paper.
Determining relevance to a query After matching population,
predictors, and outcomes between a study and a query, we calcu-
late Dstudy_phenotype(study, query) as a function of (Dpop, Dpredictor,
Doutcome). For browsing, the relative importance of population, pre-
dictor, and outcomes may vary from query to query. When a scien-
tist is designing a new study, Dpredictor and Doutcome take on far
more importance than Dpop. To quantify the overall match of a
set of studies to a given query, we compute the average
Dstudy_phenotype(study, query).
4.2.2. Matching a study’s phenotype against another study to
determine similarity
As discussed in Section 2.5, interpreting clinical research for
application to care or policy should involve interpreting a body
of evidence. In systematic reviews, care must be taken that the
studies included for synthesis are methodologically and clinically‘‘similar’’ because heterogeneity contributes to statistical heteroge-
neity [30] and affects the applicability of the ﬁndings to patients.
Thus, the notion of similarity is at the heart of evidence synthesis,
yet there exists no formal conceptualization or metrics for this
foundational notion.
Through the methods described above, though, OCRe and ERGO
Annotation provide a foundation for computing similarity. Concep-
tually, relevance and similarity are closely related. Essentially, to
ﬁnd the similarity of studyA and studyB we can replace S(query)
with S(studyB) and generate the same distance metrics as for rele-
vance. The overall relevance of a set of studies against a query can
then be generalized to the similarity between two sets of studies.
4.2.3. Matching a study’s phenotype against patient data
Eligibility determination can be seen from the perspective of a
study or that of a subject. In the former case, the problem is to ﬁnd
the cohort of patients that may satisfy the eligibility criteria of a
study. In the latter case, the problem is to identify those studies
for which a person, whose state can be represented as a conjunc-
tion of predicates, may be eligible. We have argued [65] that the
cohort identiﬁcation task—screening a database of patient infor-
mation to ﬁnd potentially eligible participants—is best done with
a conventional technology like relational databases, while the
‘‘study ﬁnding’’ task can be seen as a subsumption problem solv-
able using a description logic reasoner.
4.2.3.1. Cohort identiﬁcation. The cohort identiﬁcation task can be
performed using OCRe and ERGO Annotations with these steps:
1. Transforming eligibility criteria from text into ERGO Annotation
as described in Section 3.3.
2. Obtaining the local relational schema for patient data (e.g., a
medication table containing drug names and codes, the dose
and frequency of taking the drug, and the start and end times
of the prescription).
3. Making assumptions regarding terminologies, e.g., problems are
speciﬁed as ICD-9 codes.
4. Developing rules for assigning ERGO Annotation terms to tables
in the patient data model (e.g., assigning terms whose UMLS
semantic type was Disease or Syndrome to terms in the Prob-
lemList table).
5. Creating a Hierarchy table that speciﬁed the UMLS terms as the
ancestor(s) for each ICD-9 and drug code corresponding to a
patient’s problems and medications.
Steps 2 through 5 are more fully described in [65]. We have ex-
tended this work to address eligibility criteria with temporal rela-
tionships. For the criterion ‘‘Bone marrow toxicity 3 weeks after
end of chemotherapy’’, for example, we would start with its OCRe
representation in ERGO Annotation, decompose the representation
to ﬁnd noun phrases (as coded information), and add their corre-
sponding tables in the patient data model to the FROM part of
the query. We would use the Hierarchy table to map the terms
in the database (e.g., codes for ‘‘neutropenia’’ or codes for speciﬁc
drugs like ‘‘methotrexate’’ and ‘‘cytoxan’’) and the terms in the cri-
terion (e.g., code for ‘‘Bone marrow toxicity’’ or ‘‘Chemotherapy’’).
Finally, exploiting the structure of the timepoint constraint and
using knowledge of the target SQL implementation, we would cre-
ate an SQL query of the form:SELECT ⁄ FROM ProblemList as p, Medication asm, Hierarchy
as h
WHERE p.problem_name = h.descendant and h.ancestor =
code for ‘‘Bone marrow toxicity’’ and
m.drug_name = h.descendant and h.ancestor = code for
‘‘Chemotherapy’’ and
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experiences with templated expression languages suggest that
automated generation of queries for common constraint patterns
is very feasible [90].
4.2.3.2. Searching for Applicable Studies to Enroll In. Our earlier work
showed how non-temporal ERGO Annotations can be transformed
into OWL expressions [65]. To use a description logic reasoner to
satisfy the ‘‘study ﬁnding’’ use case, we start by creating ERGO
Annotations of all the eligibility criteria of the potential studies.
For each study, the conjunction of the transformed OWL expres-
sions for the inclusion criteria and the negation of the exclusion
criteria approximates the characteristics of the study’s target pop-
ulation. A query for studies based on a set of patient characteristics
(e.g., studies that include subjects who are pre-diabetic and have
LDL below a certain threshold), formulated as an OWL expression,
can be resolved by a description logic reasoner by ﬁnding all stud-
ies whose associated OWL eligibility expressions are subsumed by
the query expression.
4.3. Evidentiary reasoning
Our OCRe work to date has focused on modeling study design
features to support data description and data sharing for scientiﬁc
purposes. As a knowledge representation, however, OCRe can also
provide value for knowledge-based decision support. To show this
value, we are extending OCRe to include concepts related to sta-
tistical inference and structural and confounding biases, as well as
developing computational methods for evidentiary reasoning to
provide decision support for critiquing study designs. First, we
explicitly model the notion of an inference as the result of a sta-
tistical analysis of dependent and independent variables. Each
study design speciﬁes many inferences. Next, inferences are at
risk of bias (a systematic deviation away from the true value).
The types of bias that each inference is at risk for depends on
the study’s design type (from our study design typology, Sec-
tion 3.2.1) and on the clinical content of the inference. We are
extending OCRe with a typology of bias and constraining speciﬁc
types of biases to speciﬁc study design types. Examples of high-
level bias classes include selection, information, allocation, and
detection bias [91] . In addition, we model the notion of a con-
founder as variables measured by the study protocol and used
as covariates in inferential analyses.
This modeling of biases and confounding expressed in OCRe
terms provides a ﬁrst-ever ontological conceptualization of eviden-
tiary reasoning, and is an important component for any informatics
foundation for clinical research science.5. Discussion
In this paper, we have shown that OCRe can capture detailed
abstract study protocol information, which can yield numerous
beneﬁts along the entire scientiﬁc lifecycle of human studies. For
the Design phase, OCRe-based models of the design of past and
ongoing studies can help researchers retrieve, critique, and inter-
pret the evidence base to more quickly iterate towards a worth-
while question to investigate. For Study Execution, the notion of
matching study phenotypes to clinical phenotypes can assist with
cohort identiﬁcation and eligibility determination. For Study Inter-
pretation, OCRe offers a common semantics for study protocol
reporting, federated search and retrieval, and for semi-automated
methods for evidentiary reasoning. Finally, for Study Application,
OCRe-based study phenotypes can be useful for determiningstudy’s applicability to patients with matching clinical phenotypes.
The fact that we can describe how OCRe applies to such a broad
range of applications is preliminary evidence of OCRe’s breadth,
depth, and utility. Our ongoing program of research aims to dem-
onstrate and evaluate OCRe’s ability to serve as a common infor-
matics foundation for the science of clinical research.
The main difference between OCRe and other foundational
models for clinical research informatics (e.g., BRIDG, CDISC, OBX,
ClinicalTrials.gov XSD) is that OCRe takes a logic-oriented onto-
logical modeling approach that mostly consists of logical state-
ments about the design of human studies. The other models
take an information model approach that more directly helps
adopters achieve interoperability in data exchange and applica-
tion development, but with less support for computational rea-
soning. OCRe also differs from other models in scope and
domain of coverage. Compared to BRIDG, which focuses on oper-
ational support of protocol-driven regulated research, OCRe mod-
els study-design features more deeply for scientiﬁc purposes and
covers both interventional and observational studies. BRIDG, how-
ever, models business processes and makes other distinctions
necessary for supporting study execution and regulatory reporting
of primarily interventional studies. CDISC’s Protocol Representa-
tion Model is derivative of BRIDG and the same comparisons ap-
ply. OBX models results data, which OCRe does not yet do, but has
limited depth of modeling of study design features. ClinicalTri-
als.gov covers administrative and study design information, but
its modeling of study design lacks depth and is rife with inconsis-
tencies and ambiguities [7,76]. Overall, the BRIDG and CDISC
information models are best for supporting study execution and
regulatory reporting. The ClinicalTrials.gov model is important be-
cause ClinicalTrials.gov is the world’s largest collection of study
design information. Many other data models exist for various sys-
tems, but to our knowledge none have the breadth, scope, and
rigor of modeling that OCRe has for the explicit purpose of sup-
porting the science of clinical research.
ERGO Annotation is an example of OCRe’s modeling power. This
specialized part of OCRe tackles the difﬁcult challenge of repre-
senting eligibility criteria, which often exhibit high semantic com-
plexity. ERGO Annotation has a simple information model that
makes distinctions regarding the structure of the criterion (e.g.,
existence of logical connectors, numerical comparisons) while
leaving much of the semantics to noun phrases that are captured
by terminological expressions. Other approaches for expressing
clinical trial eligibility criteria such as Weng [43] and Milian [92]
use more detailed information models and can use query tem-
plates for eligibility determination and for authoring criteria, while
Huang’s approach uses Prolog rules as the model [93]. Weng’s
EliXR is notable for using a data-driven approach to discover
semantic patterns in a collection of textual eligibility criteria which
are then organized into a semantic network with rich and ﬁne-
grained semantic knowledge. The detailed patterns developed by
Milian can be parsed by NLP methods but the patterns are suitable
only for speciﬁc clinical domains. In contrast to the above-men-
tioned approaches, ERGO Annotation can support OWL-based clas-
siﬁcation reasoning once ERGO Annotations are transformed into
OWL expressions, as we have previously shown [65]. Our semi-
automated approach is also more scalable than Huang’s and other
similar approaches that use existing rule-based languages (such as
Drools), which rely on manual crafting of rule criteria from the
source text.
There are three other high-level ways in which our OCRe
work is distinct. First, our work conceptualizes and renders
study designs and eligibility criteria as structures to be repre-
sented, searched, visualized, analyzed, and reasoned about in
their own right. This approach contrasts with the more common
approach of focusing computational attention almost exclusively
I. Sim et al. / Journal of Biomedical Informatics 52 (2014) 78–91 89on results data [94,95] even though searching and analyzing
study design information is a prerequisite for making sense of
results data.
Second, while there have been heuristic and machine-learning
approaches to determining the relevance of studies to a search
query [96,97] many of the approaches require training a classiﬁer
against a hand-coded gold standard, which limits their scalability.
In contrast, we exploit OCRe’s more granular modeling to directly
match study features against a PICO query, and to deﬁne relevance
matching more sharply than is possible using only article key-
words. Our approach offers a general, scalable, high-throughput
method for determining ‘‘PICO relevance’’, which is of direct inter-
est to clinical researchers. Moreover, the same approach is useful
for cohort identiﬁcation, eligibility determination, and similarity
determination, such that once a study’s eligibility criteria are coded
in ERGO Annotation, both the instance data and the methods can
be reused across multiple use cases.
Finally, we know of no other group that is integrating the con-
ceptualization of bias and clinical confounding with clinical re-
search informatics models. This integration is crucial for enabling
ﬂuid support for a learning health system in which clinical re-
search and methodologically rigorous evidence-based care are
two sides of the same coin.5.1. Limitations
OCRe continues to be a work in progress. The study design
typology has been revised since its pilot evaluation and needs re-
newed validation. Our proposed matching methods have not been
tested. Our work on modeling sources of bias is early and a proof of
concept is still needed on using OCRe as a valid way to organize
and index biases and clinical confounders for a wide range of study
types. Above all, we have not yet modeled summary or individual-
patient level results in OCRe, although the stubs for doing so are al-
ready present.5.2. Current and future work
Our OCRe work is currently focused on three main objectives:
(1) deployment into real use environments; (2) modeling, visuali-
zation, and computational methods for evidentiary reasoning; and
(3) modeling of results data. OCRe is being incorporated into
AHRQ’s Systematic Review Data Repository (SRDR) system, which
is a workﬂow support system and study results repository
[56]. Exploratory work is continuing on using OCRe as the com-
mon semantics for Cochrane Collaboration’s Central Register of
Studies, and for data sharing between SRDR and the Cochrane
Collaboration.
In the longer term, OCRe’s greatest value will be to underpin all
ﬁve phases of the study lifecycle within a learning health system,
such that study and clinical phenotypes can be matched and inte-
grated during the processes of care. A step towards this vision is
that OCRe will be used as the semantic foundation for evidence
in the Open mHealth architecture for mobile health [98]. The goal
is ‘‘embedded evaluation:’’ large and small-scale patient-centered
studies can be conducted using mobile and sensing technology to
‘‘embed’’ the collection of evidence into daily life, where health
prevention and chronic disease are most salient [60]. OCRe will
be used to index software modules corresponding to data or func-
tional elements of study designs (e.g., randomization, baseline
characteristics), shared variable libraries, and protocol libraries.
Our ﬁrst project is using OCRe to inform the modular construction
of a mobile-based system for n-of-1 studies for chronic pain in the
PREEMPT project [99].6. Conclusion
Now is an auspicious time for clinical research informatics to be
grounded on an ontology for the science of clinical research. Tech-
nically, the science of ontologies is maturing [100] with tools like
BioPortal [101]. Both US and European policies are spurring greater
results reporting not just as PDFs but also directly into databases.
Reproducible research and other initiatives are pushing for the
sharing of protocol information as well as results data. As more
clinical research data and information become shared and comput-
able, OCRe provides well-motivated and well-formed semantics at
the core of the science of clinical research to drive and integrate all
phases of the study lifecycle. We have shown that with its breadth
and richness, OCRe is a foundational informatics framework for
clinical research and the application of evidence in a learning
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